PenKid Biomarker Enhances Kidney Function Assessment in ICU Settings

SphingoTec GmbH has released real-world data underscoring the efficacy of Proenkephalin A 119–159 (penKid) for assessing kidney function in ICUs. Implemented in over 4,000 patients, penKid demonstrates the capacity to predict acute kidney injury (AKI) and assess renal function, surpassing traditional markers like serum creatinine.

The use of penKid, especially beneficial for those with normal serum creatinine levels, allows for timely identification of high-risk patients, crucial for minimizing severe outcomes. Studies conducted at University Hospital Aachen reveal that penKid maintains accuracy under renal replacement therapy (RRT), guiding critical care decisions.

Notably, international recognition, including support from the Mayo Clinic, reinforces penKid's potential. This recognition stems from penKid's ability to provide rapid diagnostic insights, crucial for reducing unnecessary RRT interventions, and optimizing patient outcomes.